BrainEye, a mobile application initially designed for assessing sports-related head injuries, is now undergoing clinical trials at The Alfred Hospital in Melbourne to evaluate its efficacy in detecting and monitoring neurological disorders. The app digitizes the traditional eye movement test, condensing it to 60 seconds on a mobile device and utilizing AI to analyze over 20 ocular biomarkers.
The trials aim to recruit 500 participants with various neurological conditions, such as Alzheimer’s disease and Parkinson’s disease. Data from the trials will aid BrainEye in developing a commercial product for community use, facilitating early detection of neurological diseases. By comparing biomarkers to those of mentally healthy individuals, BrainEye seeks to refine its understanding of normal and abnormal brain functions.
Previously focused on sports-related concussions, BrainEye now aims to expand its application to healthcare, potentially revolutionizing early disease monitoring. Neurologists anticipate that this innovative technology could become a valuable tool for monitoring disease progression in various neurological conditions.
Click here to read the original news story.